<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Terbutaline: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Terbutaline: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Terbutaline: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11079" href="/d/html/11079.html" rel="external">see "Terbutaline: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12826" href="/d/html/12826.html" rel="external">see "Terbutaline: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F14640925"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Prolonged tocolysis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Terbutaline has not been approved and should not be used for prolonged tocolysis (beyond 48 to 72 hours). In particular, terbutaline should not be used for maintenance tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema, and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868361"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Bricanyl Turbuhaler</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F225725"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote, Extravasation;</li>
<li>
                        Beta<sub>2</sub> Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F225681"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5cacaaf-4d9c-472e-bb82-9b6779d8e595">Asthma, refractory or severe exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, refractory or severe exacerbation (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Rarely used and based on limited data; may use in patients whose symptoms are refractory to standard therapy and who are in impending respiratory arrest. May also consider in patients with severe exacerbations who are unable to use inhaled bronchodilators (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32222313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32222313'])">Ref</a></span>). Do not use in combination with parenteral epinephrine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> Initial: 0.25 mg once; if severe symptoms persist after initial dose, may repeat every 20 minutes for a total of 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32222313','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32222313','lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3cd4a4d-5af6-4536-bce0-87b0d8ff49be">Asthma, intermittent symptom relief</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, intermittent symptom relief (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An alternative short-acting inhaled beta agonist or rapid-onset long-acting beta agonist/inhaled steroid combination is preferred. Use on an as-needed basis (reliever therapy) rather than regularly scheduled (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dry powder inhaler (0.5 mg/actuation) (Canadian product): <b>Oral inhalation:</b> One inhalation with spacer every 4 hours as needed; if dose is not effective after 5 minutes, may repeat. If second dose is not effective, consult health care provider immediately (maximum dose: 6 inhalations/day). <b>Note:</b> If adequate relief is not obtained with previously effective dose or duration of effect is &lt;3 hours, patient should be reassessed promptly; may indicate worsening asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.1','lexi-content-ref-GINA.3','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.1','lexi-content-ref-GINA.3','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 5 mg 3 times daily (~6-hour intervals); if side effects occur, reduce dose to 2.5 mg 3 times daily; maximum daily dose: 15 mg/day. <b>Note: </b>Clinical practice guidelines do not recommend oral short-acting beta-agonists or nonselective beta-agonists (including oral terbutaline) for routine management and treatment of asthma due to slower onset of action and higher risk of adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.3','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.3','lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1901cf90-c698-4c4c-8e1d-8306235a6403">Extravasation management, sympathomimetic vasoconstrictors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management, sympathomimetic vasoconstrictors (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Large extravasations: <b>SUBQ:</b> Infiltrate affected extravasation area with terbutaline 1 mg using a solution of terbutaline 1 mg diluted in 10 mL NS (administration volume varied from 3 to 10 mL); may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775','lexi-content-ref-9928712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775','lexi-content-ref-9928712'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Small/distal extravasations: <b>SUBQ:</b> Infiltrate affected extravasation area with terbutaline 0.5 mg using a solution of terbutaline 1 mg diluted in 1 mL NS; may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775','lexi-content-ref-9928712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775','lexi-content-ref-9928712'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d539b92-9744-40f5-b60b-099bf8be5b0f">Tocolysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tocolysis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Only for acute, short-term use (≤72 hours).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 2.5 to 5 <b>mcg</b>/minute; increase gradually every 20 to 30 minutes by 2.5 to 5 <b>mcg</b>/minute up to a maximum of 25 <b>mcg</b>/minute; decrease to the lowest effective dose once contractions are controlled (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24578236','lexi-content-ref-8437965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24578236','lexi-content-ref-8437965'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 0.25 mg every 20 minutes to 3 hours; hold for pulse &gt;120 beats per minute. Terbutaline has not been approved for and should not be used for prolonged tocolysis (beyond 48 to 72 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27661654','lexi-content-ref-11100296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27661654','lexi-content-ref-11100296'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991668"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988976"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F225682"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F225702"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12826" href="/d/html/12826.html" rel="external">see "Terbutaline: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85b2fb27-1a4a-40d6-b8b5-ab95601995d8">Asthma, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, acute exacerbation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Continuous infusion: Limited data available, optimal dose not defined, efficacy results variable: Children and Adolescents: Initial: IV bolus dose: 4 to 10 mcg/kg followed by continuous infusion of 0.2 to 0.4 mcg/kg/minute, titrate by 0.1 to 0.2 mcg/kg/minute increments as frequently as every 30 minutes based on patient response or toxicity. Usual maximum dose is 5 mcg/kg/minute; however, doses as high as 10 mcg/kg/minute have been described; monitor closely for adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17572517','lexi-content-ref-16502398','lexi-content-ref-26959519','lexi-content-ref-16203672','lexi-content-ref-25164315','lexi-content-ref-9781734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17572517','lexi-content-ref-16502398','lexi-content-ref-26959519','lexi-content-ref-16203672','lexi-content-ref-25164315','lexi-content-ref-9781734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 and Adolescents &lt;15 years: 2.5 mg three times daily; maximum daily dose: 7.5 mg/24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents ≥15 years: 5 mg three times daily (approximately every 6 hours); reduce dose to 2.5 mg three times daily if side effects occur; maximum daily dose: 15 mg/24 hours</p>
<p style="text-indent:-2em;margin-left:4em;">SubQ:</p>
<p style="text-indent:-2em;margin-left:6em;">Children: Limited data available: SubQ: 0.01 mg/kg/dose every 20 minutes for 3 doses; may repeat every 2 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: SubQ: 0.25 mg/dose; may repeat every 20 minutes for up to 3 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Oral inhalation: <i>Canadian labeling: </i>Bricanyl Turbuhaler [Canadian product]: Children ≥6 years and Adolescents: 1 inhalation (0.5 mg) as needed; if not effective after 5 minutes may repeat dose. If second dose is not effective, consult health care provider immediately. Maximum daily dose: 6 inhalations/24 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192875"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51192876"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F225646"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Nervousness, restlessness</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium, increased serum glucose</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness, drowsiness, headache, insomnia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, nausea, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps, weakness</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Cardiac arrhythmia, chest pain, hyperglycemia (preterm labor), hypokalemia (preterm labor), hypotension (preterm labor), ischemic heart disease (preterm labor), lactic acidosis (Smith 2019), myocardial infarction (preterm labor), paradoxical bronchospasm, pulmonary edema (preterm labor)</p></div>
<div class="block coi drugH1Div" id="F225661"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to terbutaline, sympathomimetic amines, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Additional contraindications: Prolonged tocolysis (&gt;48 to 72 hours), especially for maintenance in the outpatient setting.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Additional contraindications: Acute or maintenance tocolysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in the US labeling): Hypersensitivity to lactose; history of tachyarrhythmias; as tocolytic in patients at risk of premature labor or threatened abortion.</p></div>
<div class="block war drugH1Div" id="F225643"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: Paradoxical bronchospasm that may be life-threatening may rarely occur with use of inhaled bronchodilating agents; this reaction should be distinguished from inadequate response. Discontinue immediately if paradoxical bronchospasm occurs and institute alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serious effects/fatalities: Do not exceed recommended dose or frequency; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Appropriate use: When used as a bronchodilator, optimize anti-inflammatory treatment before initiating maintenance treatment with terbutaline. Do not use as a component of chronic therapy without an anti-inflammatory agent.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, hypertension, heart failure); beta-agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta<sub>2</sub>-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; beta<sub>2</sub>-agonists may increase serum glucose and aggravate preexisting diabetes and ketoacidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with glaucoma; may elevate intraocular pressure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use with caution in hyperthyroidism; may stimulate thyroid activity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Use with caution in patients with hypokalemia; beta<sub>2</sub>-agonists may transiently decrease serum potassium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose; Bricanyl Turbuhaler [Canadian product]: Dry powder inhalers may contain lactose; hypersensitivity reactions have been reported in patients with milk protein allergy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use may indicate deterioration of asthma, and treatment must not be delayed.</p></div>
<div class="block foc drugH1Div" id="F225654"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (1 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg</p></div>
<div class="block geq drugH1Div" id="F225639"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F225663"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Terbutaline Sulfate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $1.56 - $23.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Terbutaline Sulfate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $5.44 - $13.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $6.65 - $16.77</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868362"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder Breath Activated, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bricanyl Turbuhaler: 0.5 mg/actuation (1 ea)</p></div>
<div class="block adm drugH1Div" id="F225657"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral inhalation:</b> Dry powder inhaler: Bricanyl Turbuhaler [Canadian product]: When ready to use, remove lid and hold inhaler upright. Turn blue grip as far as it will go in one direction, then turn blue grip in the opposite direction until you hear a click; repeat this step a second time and then inhaler is ready to use. Exhale fully (not into inhaler) and place lips around mouthpiece and inhale deeply; remove inhaler from mouth prior to exhaling. Rinse mouth with water after use (do not swallow). If inhaler is dropped or shaken, or if patient exhales into the inhaler after a dose is loaded, the dose will be lost and a new dose should be loaded and inhaled. Clean mouthpiece once weekly with a dry tissue; do not use water or any other fluid to clean and keep inhaler dry. First appearance of red mark in dose indicator indicates that 10 doses remain; discard inhaler when the dose indicator reaches "0".</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> Administer injections into the lateral deltoid area.</p>
<p style="text-indent:-2em;margin-left:2em;">Extravasation management, sympathomimetic vasopressors (off-label use): Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Large extravasations: <b>SUBQ:</b> Infiltrate affected extravasation area with terbutaline 1 mg using a solution of terbutaline 1 mg diluted in 10 mL NS (administration volume varied from 3 to 10 mL); may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775','lexi-content-ref-9928712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775','lexi-content-ref-9928712'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Small/distal extravasations: <b>SUBQ:</b> Infiltrate affected extravasation area with terbutaline 0.5 mg using a solution of terbutaline 1 mg diluted in 1 mL NS; may repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775','lexi-content-ref-9928712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775','lexi-content-ref-9928712'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613907"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer without regard to food; administer around-the-clock to promote less variation in peak and trough serum levels.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">Direct IV injection: Administer undiluted over 5 to 10 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer via an infusion pump at a concentration ≤1 mg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17572517','lexi-content-ref-25147175','lexi-content-ref-Sinclair-Pingel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17572517','lexi-content-ref-25147175','lexi-content-ref-Sinclair-Pingel.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Inhalation: Bricanyl Turbuhaler [Canadian product]: To prepare inhaler prior to use, load dose by holding inhaler in upright position and turn blue grip as far as it will go in one direction and then turn it as far as it will go in the other direction. Prior to first use, this procedure should be done twice; with subsequent dosing, perform this procedure once. Clicking sound means inhaler is loaded with dose and ready for use. Place mouthpiece between teeth and close lips over mouthpiece. Inhale deeply and forcefully. Do not exhale through inhaler. If the Turbuhaler is dropped, shaken, or breathed into after it is loaded, the dose will be lost and a new dose will need to be loaded. When a red mark appears in the dose indicator window, 20 doses are left. When the red mark reaches the bottom of the window, the inhaler should be discarded.</p></div>
<div class="block use drugH1Div" id="F225655"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma/Bronchospasm:</b> Prevention and reversal of bronchospasm in patients ≥12 years of age with asthma and reversible bronchospasm associated with bronchitis and emphysema <b>or </b>≥6 years of age (Bricanyl Turbuhaler [Canadian product]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: Asthma (oral product):</b> Although included as an FDA-approved use in the manufacturer’s prescribing information for asthma and reversible bronchospasm associated with bronchitis and emphysema, oral short-acting beta-agonists or nonselective beta-agonists (including oral terbutaline) are not recommended due to slower onset of action and higher risk of adverse effects (GINA 2023; NAEPP 2007).</p></div>
<div class="block off-label drugH1Div" id="F25470443"><span class="drugH1">Use: Off-Label: Adult</span><p>Extravasation management, sympathomimetic vasoconstrictors; Tocolysis</p></div>
<div class="block mst drugH1Div" id="F225734"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Brethine may be confused with Methergine</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Terbutaline may be confused with terbinafine, TOLBUTamide</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Terbutaline and methylergonovine parenteral dosage forms look similar. Due to their contrasting indications, use care when administering these agents.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300114"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F225648"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azithromycin (Systemic): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Azithromycin (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbetocin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Carbetocin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Chloroquine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Clofazimine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Dabrafenib.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Domperidone.  Management: Consider alternatives to this drug combination. If combined, monitor for QTc interval prolongation and ventricular arrhythmias. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etelcalcetide: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Etelcalcetide.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Fluorouracil Products.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gadobenate Dimeglumine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Gadobenate Dimeglumine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Halofantrine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Haloperidol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotuzumab Ozogamicin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Inotuzumab Ozogamicin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Lofexidine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meglumine Antimoniate: May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta2-Agonists (Short-Acting) may diminish the therapeutic effect of Methacholine.  Management: Hold short-acting beta<sub>2</sub> agonists for 6 hours before methacholine use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Midostaurin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Ondansetron.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Oxytocin.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentamidine (Systemic): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Pentamidine (Systemic).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Piperaquine.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probucol: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Probucol.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): Terbutaline may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Consider alternatives to this combination. Patients with other risk factors (eg, older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations) are likely at greater risk for these toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antidepressants (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Antipsychotics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Class IC Antiarrhythmics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Class IC Antiarrhythmics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-Prolonging Inhalational Anesthetics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Kinase Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk) may increase the serum concentration of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Quinolone Antibiotics (Moderate Risk): QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of QT-prolonging Quinolone Antibiotics (Moderate Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Strong CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents (Moderate Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotalol: Terbutaline may enhance the QTc-prolonging effect of Sotalol. Sotalol may diminish the therapeutic effect of Terbutaline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Terbutaline may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta2-Agonists may enhance the adverse/toxic effect of Theophylline Derivatives. Specifically, sympathomimetic effects may be increased. Theophylline Derivatives may enhance the hypokalemic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: QT-prolonging Miscellaneous Agents (Moderate Risk) may enhance the QTc-prolonging effect of Toremifene.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F14206279"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Terbutaline crosses the placenta; umbilical cord concentrations are ~11% to 48% of maternal blood levels.</p>
<p style="text-indent:0em;margin-top:2em;">Terbutaline may affect uterine contractility; use caution if needed to control bronchospasm in pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled asthma is associated with adverse events in pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low-birth-weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes). Although short acting beta-2 agonists should be used to treat acute asthma exacerbations in pregnant patients, agents other than terbutaline are preferred (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Terbutaline injection has not been approved for and should not be used for prolonged tocolysis (beyond 48 to 72 hours). Oral terbutaline sulfate has not been approved and should not be used for acute or maintenance tocolysis. Terbutaline should not be used for maintenance tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline to pregnant patients. Maternal adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema, and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may also occur. Terbutaline has been used in the management of preterm labor. Tocolytics may be used for the short-term prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth (ACOG 2016).</p></div>
<div class="block brc drugH1Div" id="F13763352"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Terbutaline is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Terbutaline breast milk concentrations are similar to or higher than those in the maternal plasma. Based on information from four cases, exposure to the breastfed infant would be &lt;1% of the weight-adjusted maternal dose. Adverse events were not observed in nursing infants (Boréus 1982; Lönnerholm 1982).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that terbutaline be used in breastfeeding patients only if the potential benefit to the mother outweighs the possible risk to the infant.</p>
<p style="text-indent:-2em;margin-left:2em;">Terbutaline is considered probably acceptable for use while breastfeeding (ERS/TSANZ [Middleton 2020]).</p></div>
<div class="block mop drugH1Div" id="F225652"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests; shortness of breath; BP, heart rate; CNS stimulation; serum glucose, serum potassium; monitor for signs and symptoms of pulmonary edema (when used as a tocolytic). If used for extravasation management, monitor and document extravasation site.</p></div>
<div class="block pha drugH1Div" id="F225642"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Relaxes bronchial and uterine smooth muscle by action on beta<sub>2</sub>-receptors with less effect on heart rate</p></div>
<div class="block phk drugH1Div" id="F225660"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: 30 to 45 minutes; SubQ: 6 to 15 minute; Inhalation: 5 minutes (maximum effect: 15 to 60 minutes).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Oral: 4 to 8 hours; Oral inhalation: 3 to 6 hours; SubQ: 1.5 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: 33% to 50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 25%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to inactive sulfate conjugates.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SubQ doses are more bioavailable than oral.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 5.7 hours (range: 2.9 to 14 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: SubQ: 0.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~60% as unchanged drug); feces.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038836"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Bricanyl-duriles</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Tervent</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Greencanyl</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Hui bang | Terbutaline | Terbutaline Sulphate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Sulter | Terburop | Terbutalina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Asthmoprotect | Bricanyl | Contimit | Terbul | Terbutalin al | Terbutalin ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Terburop</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Terburop</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Aironyl | Bricanyl | Terbutaline | Terbutanyl</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Tedipulmo | Terbasmin | Terbasmin ern</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Bricanyl lp</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Monovent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dracanyl</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apt Terbutaline | Ataline | Bricanyl | Britaline | Brothines | Butaline | Butylin | Dhatalin | Eurobutal | Terbron | Terbuline | Terbuta | Terbutaline | Tertal | Uni-Breth</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Asmabet | Asthmoprotect | Bintasma | Brasmatic | Bricasma | Forasma | Lasmalin | Nairet | Neosma | Prosmalin | Pulmobron | Sedakter | Tabas | Terasma | Tismalin | Yarisma</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Bricalin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Terbutaline Sulphate | Tetrasma</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Terbasmin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Talin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Convon | Naropatin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Beta-2 | Bricanyl</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Butaline</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Terbul</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Taziken</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Anvelin | Asmalin | Ataline | Bricanyl | Britaline | Bronkine | Brontaline | Bucanil | Butaline | Butanil | Butylin | Pritalin | Terbron | Terbuline | Terbutaline | Terbutaline Sulphate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Terbutalin al</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Astebron | Blucodil | Bricanyl | Bronchodam | Lungex | Pulmoxcel | Terbulin | Terbutaline | Terbutaline Am-Europharma | Terbutaline Scheele | Ventryl</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Asmanyl | Brethin | Bricanyl | Respair | Terbulin | Terbutascot | Terbutil | Tesmic | Ventair</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Brethine | Terbutaline</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aironyl | Bricanyl | Bronclyn | Dilanyl | Neoterb | Talin | Terbu-Q</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aironyl | Bricanyl</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Respirol</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Anvelin | Asmalin | Ataline | Bricanyl | Bucanil | Butylin | Dhatalin | Terbutaline</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Asmaline | Asmarin | Asmotab | Asthamsian | Asthermine | Asthmic | Asthmotab | B-lene | Baltic | Becasyl | Biterine | Bricanyl | Britaline | Broncho | Broncholine | Bronchonil | Bronchonyl | Bronco Asmo | Bronic | Bucanyl | Bucaril | Buline | Butalin | Butaline | Butanyl | Byterine | Cabrinyl | Cocolax | Fasma | Framagon | H ma | Manotaline | P-Canil | Piptanyl | Proasma-t | Terbaline | Terbron | Terbu | Terbulin | Terbuline | Terbumed | Terbuno | Terbusin | Terbutab | Terbutal | Terbutaline | Terbuton | Terlain | Tolbin | Unires</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Talin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Berocol | Brandyl | Bricanyl | Bricardyl | Brothine | Glin | Soter | Terbeline | Terbuline | Tersultran | Tusoloc</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl | Nortol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Bricanyl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27661654">
<a name="27661654"></a>American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 171: Management of Preterm Labor. <i>Obstet Gynecol</i>. 2016;128(4):e155-e164. doi:10.097/AOG.0000000000001711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/27661654/pubmed" id="27661654" target="_blank">27661654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11127122">
<a name="11127122"></a>Berkman ND, Thorp JM Jr, Hartmann KE, et al. Management of preterm labor. <i>Evid Rep Technol Assess (Summ)</i>. 2000;(18):1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/11127122/pubmed" id="11127122" target="_blank">11127122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17572517">
<a name="17572517"></a>Bogie AL, Towne D, Luckett PM, Abramo TJ, Wiebe RA. Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous high-dose nebulized albuterol for status asthmaticus. <i>Pediatr Emerg Care</i>. 2007;23(6):355-361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/17572517/pubmed" id="17572517" target="_blank">17572517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6435957">
<a name="6435957"></a>Bohn D, Kalloghlian A, Jenkins J, et al. Intravenous Salbutamol in the Treatment of Status Asthmaticus in Children. <i>Crit Care Med</i>. 1984;12(10):892-896.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/6435957/pubmed" id="6435957" target="_blank">6435957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7082542">
<a name="7082542"></a>Boréus LO, de Château PU. Terbutaline in Breast Milk. <i>Br J Clin Pharmacol</i>. 1982;13(5):731-732.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/7082542/pubmed" id="7082542" target="_blank">7082542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bricanyl.1">
<a name="Bricanyl.1"></a>Bricanyl Turbuhaler (terbutaline) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3276242">
<a name="3276242"></a>Canny GJ, Levison H. Aerosols - Therapeutic Use and Delivery in Childhood Asthma. <i>Ann Allergy</i>. 1988;60(1):11-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/3276242/pubmed" id="3276242" target="_blank">3276242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16502398">
<a name="16502398"></a>Carroll CL, Schramm CM. Protocol-based titration of intravenous terbutaline decreases length of stay in pediatric status asthmaticus. <i>Pediatr Pulmonol</i>. 2006;41(4):350-356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/16502398/pubmed" id="16502398" target="_blank">16502398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26959519">
<a name="26959519"></a>Doymaz S, Schneider J. Safety of terbutaline for treatment of acute severe pediatric asthma. <i>Pediatr Emerg Care</i>. 2018;34(5):299-302.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/26959519/pubmed" id="26959519" target="_blank">26959519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fanta.1">
<a name="Fanta.1"></a>Fanta CH, Cahill KN. Acute exacerbations of asthma in adults: emergency department and inpatient management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2915294">
<a name="2915294"></a>Fuglsang G, Pedersen S, Borgstrom L. Dose-Response Relationships of I.V. Administered Terbutaline in Children With Asthma. <i>J Pediatr</i>. 1989;114(2):315-320.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/2915294/pubmed" id="2915294" target="_blank">2915294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.3">
<a name="GINA.3"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/reports/. Updated 2023. Accessed September 18, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Updated 2021. Accessed December 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2652119">
<a name="2652119"></a>Goldenhersh N, Rachelefsky GS. Childhood Asthma: Management. <i>Pediatr Rev</i>. 1989;10(9):259-267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/2652119/pubmed" id="2652119" target="_blank">2652119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9790362">
<a name="9790362"></a>Guinn DA, Goepfert AR, Owen J, et al. Terbutaline Pump Maintenance Therapy for Prevention of Preterm Delivery: A Double-Blind Trial. <i>Am J Obstet Gynecol</i>. 1998;179(4):874-878.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/9790362/pubmed" id="9790362" target="_blank">9790362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11100296">
<a name="11100296"></a>Hearne AE, Nagey DA. Therapeutic Agents in Preterm Labor: Tocolytic Agents. <i>Clin Obstet Gynecol.</i> 2000;43(4):787-801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/11100296/pubmed" id="11100296" target="_blank">11100296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16203672">
<a name="16203672"></a>Kambalapalli M, Nichani S, Upadhyayula S. Safety of intravenous terbutaline in acute severe asthma: a retrospective study. <i>Acta Paediatr</i>. 2005;94(9):1214-1217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/16203672/pubmed" id="16203672" target="_blank">16203672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2301784">
<a name="2301784"></a>Kelly HW, McWilliams BC, Katz R, et al. Safety of Frequent High Dose Nebulized Terbutaline in Children With Acute Severe Asthma. <i>Ann Allergy</i>. 1990;64(2, pt 2):229-233.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/2301784/pubmed" id="2301784" target="_blank">2301784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lam.1">
<a name="Lam.1"></a>Lam F, Gill P, Smith M, et al. Use of the Subcutaneous Terbutaline Pump for Long-Term Tocolysis. <i>Obstet Gynecol</i>. 1998;72(5):810-813.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7082541">
<a name="7082541"></a>Lönnerholm G, Lindström B. Terbutaline Excretion Into Breast Milk. <i>Br J Clin Pharmacol</i>, 1982;13(5):729-730.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/7082541/pubmed" id="7082541" target="_blank">7082541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32222313">
<a name="32222313"></a>Long B, Lentz S, Koyfman A, Gottlieb M. Evaluation and management of the critically ill adult asthmatic in the emergency department setting. <i>Am J Emerg Med</i>. 2021;44:441-451. doi:10.1016/j.ajem.2020.03.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/32222313/pubmed" id="32222313" target="_blank">32222313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24578236">
<a name="24578236"></a>Mackeen AD, Seibel-Seamon J, Muhammad J, Baxter JK, Berghella V. Tocolytics for preterm premature rupture of membranes. <i>Cochrane Database Syst Rev</i>. 2014;(2):CD007062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/24578236/pubmed" id="24578236" target="_blank">24578236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.1">
<a name="NAEPP.1"></a>National Asthma Education and Prevention Program (NAEPP) Expert Panel Report 3. Guidelines for the Diagnosis and Management of Asthma. Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. <a href="http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm" target="_blank">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2863296">
<a name="2863296"></a>Rachelefsky GS, Siegel SC. Asthma in Infants and Children - Treatment of Childhood Asthma: Part II. <i>J Allergy Clin Immunol</i>. 1985;76(3):409-425.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/2863296/pubmed" id="2863296" target="_blank">2863296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17671256">
<a name="17671256"></a>Simhav HN, Caritis SN. Prevention of Preterm Delivery. <i>N Engl J Med</i>. 2007;357(5):477-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/17671256/pubmed" id="17671256" target="_blank">17671256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sinclair-Pingel.1">
<a name="Sinclair-Pingel.1"></a>Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Order Entry System [published correction appears in <i>Hosp Pharm</i>. 2007; 42:84-85]. <i>Hosp Pharm</i>. 2006;41:1102- 106.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25164315">
<a name="25164315"></a>Singhi S, Grover S, Bansal A, Chopra K. Randomised comparison of intravenous magnesium sulphate, terbutaline and aminophylline for children with acute severe asthma. <i>Acta Paediatr</i>. 2014;103(12):1301-1306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/25164315/pubmed" id="25164315" target="_blank">25164315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31361914">
<a name="31361914"></a>Smith ZR, Horng M, Rech MA. Medication-induced hyperlactatemia and lactic acidosis: a systematic review of the literature. <i>Pharmacotherapy</i>. 2019;39(9):946-963.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/31361914/pubmed" id="31361914" target="_blank">31361914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9781734">
<a name="9781734"></a>Stephanopoulos DE, Monge R, Schell KH, Wyckoff P, Peterson BM. Continuous intravenous terbutaline for pediatric status asthmaticus. <i>Crit Care Med</i>. 1998;26(10):1744-1748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/9781734/pubmed" id="9781734" target="_blank">9781734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9928712">
<a name="9928712"></a>Stier PA, Bogner MP, Webster K, et al. Use of subcutaneous terbutaline to reverse peripheral ischemia. <i>Am J Emerg Med</i>. 1999;17(1):91-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/9928712/pubmed" id="9928712" target="_blank">9928712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Terbutaline.1">
<a name="Terbutaline.1"></a>Terbutaline sulfate injection, USP [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Terbutaline.1">
<a name="Terbutaline.1"></a>Terbutaline sulfate tablet [prescribing information]. Paramus, NJ: TWi Pharmaceuticals USA Inc; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3565860">
<a name="3565860"></a>Tipton WR, Nelson HS. Frequent Parenteral Terbutaline in the Treatment of Status Asthmaticus in Children. <i>Ann Allergy</i>. 1987;58(4):252-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/3565860/pubmed" id="3565860" target="_blank">3565860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8437965">
<a name="8437965"></a>Travis BE, McCullough JM. “Pharmacotherapy of Preterm Labor. <i>Pharmacotherapy</i>. 1993;13(1):28-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/8437965/pubmed" id="8437965" target="_blank">8437965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7584746">
<a name="7584746"></a>Zehner WJ Jr, Scott JM, Iannolo PM, et al. Terbutaline vs Albuterol for Out-of-Hospital Respiratory Distress: Randomized Double-Blind Trial. <i>Acad Emerg Med</i>. 1995;2(8):686-691.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/terbutaline-drug-information/abstract-text/7584746/pubmed" id="7584746" target="_blank">7584746</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9977 Version 295.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
